BRAF and oligodendroglioma: Survival based on molecular diagnosis showed a median survival of 9.6 years of patients with astrocytoma, 15.1 years of patients with oligodendroglioma, 1.5 years of patients with glioblastoma, 5.2 years of patients with BRAF-mutated tumors, 1.5 years of patients with H3F3A K27 M-mutated tumors (n = 9) and 2.7 years of patients with H3F3A G34 M-mutated tumors (n = 3) (Fig. 2).